Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy Virtual 2020 | Proteasome inhibitors: key drugs in multiple myeloma

Maria-Victoria Mateos • 14 May 2020
COMy Virtual 2020
Multiple Myeloma Antibodies Bortezomib Carfilzomib Daratumumab Dexamethasone Ixazomib Lenalidomide Melphalan Prednisone

Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, talks on the use of proteasome inhibitors in the eldery population, including bortezomib, carfilzomib and ixazomib. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Maria-Victoria Mateos

2:44
Dual-targeting bispecific antibody alnuctamab in R/R multiple myeloma
Maria-Victoria Mateos • 9 Dec 2023
2:26
Preliminary results of GEM2017FIT: comparing induction therapies in fit elderly patients with MM
Maria-Victoria Mateos • 9 Dec 2023
4:21
CAR-T in multiple myeloma: progress in the space and what can be done to improve patient outcomes
Maria-Victoria Mateos • 17 Feb 2024
Latest advances in T-cell engaging therapies for multiple myeloma
Adam Cohen et al. • 15 Apr 2023

Related Videos

MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals